CA
NZ
UK
AU
IND
US
GAAP operating margin was 44.9% against 42.4%, and non-GAAP operating margin was 49.1% against 48.6%. Chairperson and Chief Executive Officer Jayshree Ullal described record profitability that surpassed her own high expectations, and the chief financial officer called the quarter a trifecta of record revenue …
Selling andMarketingexpense was USD 127.0 million versus USD 129.3 million, and general and administrative expense was USD 62.0 million versus USD 69.4 million. Product development expense was USD 9.3 million versus USD 20.7 million.
Manufacture and supply revenue was USD 6,659 thousand versus USD 11,467 thousand. License andRoyaltyrevenue was USD 824 thousand versus USD 1,038 thousand, and co-development and research fees were USD 74 thousand versus USD 302 thousand.
Product sales, net, were USD 125,455 thousand versus USD 105,515 thousand. ProductSupplyRevenuewas USD 1,380 thousand, with none in the prior-year quarter. Licensing revenue was USD 216 thousand versus USD 25 thousand, and non-cashRoyaltyrevenue related to the sale of future royalties was USD 604 thousand …
Adjusted EBITDA was USD 121 million, up 2%. Growth in Life Sciences, Personal Care and Intermediates was partly offset by lowerEarningsin Specialty Additives. Average diluted shares outstanding were 46 million, unchanged from the prior-year quarter.
Gross profit was USD 119.4 million compared with USD 101.3 million, and gross margin of 77.3% was 180 basis points higher on favorable product and geographic mix. Income from operations was USD 4.4 million versus USD 0.2 million, and net income was USD 4.1 …
Merchant revenues were USD 6,998 million versus USD 6,131 million, and the company attributed the increase primarily to growth in accommodation reservation services at Booking.com and its ongoing shift from agency to merchant revenues. Agency revenues were USD 2,463 million versus USD 2,569 million, …
Adjusted R&D expenses were EUR 579 million versus EUR 479 million, reflecting greaterInvestmentin prioritized immuno-oncology and antibody-drug conjugate programs, partially offset by lower spending outside the strategic focus. On an IFRS basis, R&D expenses were EUR 748 million, with the additional EUR 169 million …
Specialty products net sales were USD 549,550 thousand versus USD 525,455 thousand, and structural products net sales were USD 263,060 thousand versus USD 223,415 thousand. Specialty products include categories such as engineered wood, moulding, siding, specialty lumber and panels, and industrial products, while structural …
Americas adjusted EBITDA was USD 365 million versus USD 398 million, and International adjusted EBITDA was USD 180 million versus USD 190 million. CEO Brian Choi said the quarter showed continued progress in fleet management, with Americas utilization the best in twenty years.
Please wait processing your request...